- GSK Validates High Throughput Format of Gentonix Bluescreen® Assay
Product News: GSK Validates High Throughput Format of Gentonix Bluescreen® AssaySpecialist in early genotoxicity screening and mechanistic follow-up, Gentronix, is pleased to announce the findings of new research published by GlaxoSmithKline (GSK) on the miniaturization and automation of BlueScreen™ HC; a proprietary assay developed by Gentronix for high throughput genotoxicity testing. Presented in the peer-reviewed Journal of Biomolecular Screening, the study demonstrates that BlueScreen-384 can reduce the need for costly and time-consuming analogue testing in more traditional genotoxicity methods such as the Ames test.
GSK researchers scaled down the assay for use with 384-microwell plates and available reader technologies in high throughput applications and showed that BlueScreen-384 provided robust, reproducible, and consistent results, supporting its use as a routine genotoxicity screening assay. Importantly, the research also demonstrated how the exploration of structure-activity relationships around a genotoxic lead molecule could be used to identify non-genotoxic analogues.
BlueScreen HC is an innovative assay from Gentronix, which uses genetically modified, human-derived cells containing the GADD45a gene coupled to Gaussia luciferase to detect the genotoxic effects of compounds with high specificity and sensitivity.
Commenting on the publication, Dr Steve Beasley, Commercial Director at Gentronix, said: “The GSK paper provides valuable insights and independent verification for the scalability of our proven BlueScreen HC technology. Additionally, the successful miniaturization of BlueScreen-384 further opens up possibilities for high throughput genotoxicity measurement across a wide range of industries.”